Utilisation and Outcomes of Eribulin in Triple-Negative Metastatic Breast Cancer (TN MBC): Real-World Findings

被引：0
|
作者：
Kish, Jonathan K. [1 ]
Mougalian, Sarah S. [2 ]
Copher, Ronda [3 ]
McAllister, Lindsay [1 ]
Wang, Zhixiao [3 ]
Janevski, Mile [4 ]
Broscious, Mary [1 ]
机构：
[1] Cardinal Hlth Specialty Solut, Dublin, OH USA
[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Eisai Australia, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [1] Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real-world findings
    Kish, J. K.
    Mougalian, S. S.
    Copher, R.
    McAllister, L.
    Zhixiao, W.
    Broscious, M.
    CANCER RESEARCH, 2017, 77
  • [2] Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer
    Skinner, Karen E.
    Haiderali, Amin
    Huang, Min
    Schwartzberg, Lee S.
    FUTURE ONCOLOGY, 2021, 17 (08) : 931 - 942
  • [3] Real-world effectiveness outcomes by race in patients with metastatic triple negative breast cancer
    Skinner, K. E.
    Dufour, R.
    Haiderali, A.
    Huang, M.
    Schwartzberg, L. S.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Experience with eribulin in triple-negative metastatic breast cancer: case studies
    Gallegos Sancho, Maria Isabel
    Marquez-Vazquez, Raul
    Sanchez-Munoz, Alfonso
    FUTURE ONCOLOGY, 2018, 14 (07) : 13 - 20
  • [5] Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer A Multi-institutional Real-world Report on Efficacy and Safety
    Valerio, Maria R.
    Arrivas Bajardi, Eugenia
    Arcara, Carmelo C.
    Borsellino, Nicolo'
    Lo Mauro, Mario
    Cipolla, Calogero
    Santarpia, Mariacarmela
    Firenze, Alberto
    Motta, Gianmarco
    Vigneri, Paolo
    Gebbia, Vittorio
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (03): : 105 - 108
  • [6] Outcomes for metastatic triple-negative (TN) breast cancer: Impact for clinical practice and trial design
    Kassam, F.
    Enright, K.
    Dent, R.
    Flynn, C.
    Myers, J.
    Fralick, M.
    Kumar, R.
    Clemons, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Real-world data on triple-negative breast cancer in Latin America and the Caribbean
    Tiscoski, Katsuki Arima
    Giacomazzi, Juliana
    Rocha, Matheus Soares
    Goessling, Gustavo
    Werutsky, Gustavo
    ECANCERMEDICALSCIENCE, 2023, 17
  • [8] Real-world outcomes of systemic therapy for advanced triple-negative breast cancer: a tertiary centre experience
    Zhang, Shuai
    Coriano, Matilde
    Mac Eochagain, Colm
    Yang, Dorothy
    Yiu, Daniel
    Ring, Alistair
    Battisti, Nicolo M. L.
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Understanding real-world treatment and outcomes in patients diagnosed with metastatic triple negative breast cancer (mTNBC).
    Skinner, Karen E.
    Walker, Mark S.
    Haiderali, Amin
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
    Punie, K.
    Kurian, A.
    Ntalla, I.
    Huynh, D. H.
    Sadetsky, N.
    Estrin, A.
    Dabrowski, E.
    Sjekloca, N.
    Lai, C.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S347 - S348
12345